- Guide to PHARMACOLOGY
Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential ustekinumab biosimilar (QX001S) in Phase 1 evaluation for psoriasis (trial registry number ChiCTR1900022127).
||An anti-IL-12B therapy approved to treat psoriasis.|
||An anti-IL-12B therapy approved to treat PsA.|
|FDA approved for the treatment of moderate-severe UC in October 2019. Results from Phase 3 clinical trial NCT02407236 showed that ustekinumab was more effective than placebo as measured by induction and maintainance of clinical remission.||2|